Skip to main content

Table 3 Simulated numbers of influenza vaccinations and outcomes in children and adults using base-case values

From: The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study

Vaccinations and outcomesa

Children (0–17 years)

Adults (18 years and over)

Scenario 1b

Scenario 2c

Difference

Scenario 1b

Scenario 2c

Difference

Vaccinations

TIV

19,297,651

1,084,672

−18,212,979

180,955,563

180,955,563

0

LAIV

0

45,637,434

45,637,434

0

0

0

Total

19,297,651

46,722,106

27,424,455

180,955,563

180,955,563

0

Epidemiological outcomes

Infections

13,830,361

4,835,746

−8,994,615 (−65.0%)

45,033,115

30,122,649

−14,910,466 (−33.1%)

Symptomatic cases

9,252,511

3,235,114

−6,017,397 (−65.0%)

30,127,153

20,152,052

−9,975,101 (−33.1%)

  1. TIV trivalent inactivated influenza vaccine; LAIV live-attenuated influenza vaccine.
  2. aAll results are estimates for the 10-year evaluation period.
  3. bScenario 1: TIV immunisation at current age-specific vaccination coverage.
  4. cScenario 2: TIV immunisation of children 2 to 17 years of age is replaced by LAIV immunisation, with coverage increasing up to 50% in three annual steps.